[A case report of both CAF and docetaxel-resistant breast cancer responding to paclitaxel weekly therapy].
A 58-year-old woman underwent CAF and docetaxel therapy for lung, liver and bone metastases from breast cancer operated on 14 years ago. Because of progressive disease due to secondary resistance to CAF and docetaxel, the patient was given three courses of paclitaxel therapy (60 mg/m2, day 1, 8, 15, repeated every 4 weeks). The paclitaxel weekly therapy brought about no adverse effects and remarkable effects against lung and liver metastases (PR). Although the duration of the response to the paclitaxel therapy was limited to about two months due to the progression of skull bone metastasis, paclitaxel weekly therapy may be effective against both CAF and docetaxel-resistant breast cancer.
Emoto
Takashi
T
Dept. of Surgery, Osaka Rosai Hospital.
Yoshikawa
Kiyoshi
K
Fujikawa
Masahiro
M
Fujii
Makoto
M
Yoshioka
Yasuhiko
Y
Hamada
Eisaku
E
Naka
Yoshihisa
Y
Komaki
Takamitu
T
D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D001943:Breast Neoplasms / Q000473:pathology*; D003520:Cyclophosphamide / Q000494:pharmacology; D000077143:Docetaxel; D004317:Doxorubicin / Q000031:analogs & derivatives / Q000494:pharmacology; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000494:pharmacology; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage* / Q000031:analogs & derivatives* / Q000494:pharmacology; D043823:Taxoids
D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D005472:Fluorouracil